Refine
Document Type
- Article (62)
- Preprint (24)
- Contribution to a Periodical (2)
Has Fulltext
- yes (88)
Is part of the Bibliography
- no (88)
Keywords
- SARS-CoV-2 (30)
- COVID-19 (20)
- Omicron (5)
- PCR (5)
- coronavirus (4)
- vaccination (4)
- antiviral therapy (3)
- Autopsy (2)
- BA.1 (2)
- COVID-19 surveillance (2)
- PRNT (2)
- SARS-CoV-2 monitoring (2)
- SARS‐CoV‐2 (2)
- corona virus (2)
- disease burden (2)
- hepatitis B (2)
- in vitro (2)
- infectivity (2)
- influenza (2)
- neutralizing antibodies (2)
- out-patient paediatrics (2)
- respiratory tract infection (2)
- saliva (2)
- sub-lineage (2)
- vaccine (2)
- 17‐OH itraconazole (1)
- 2-deoxy-d-glucose (1)
- 2019-nCoV (1)
- ACE inhibitor (1)
- ALF (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- Ag-RDT (1)
- Anti-CMV IgG (1)
- Antigen test (1)
- B.1.1.529 (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BA.4 (1)
- BA.5 (1)
- BNT162b2 (1)
- BNT2b2 (1)
- Bio safety (1)
- Biomarkers (1)
- CD47 (1)
- CMVepidemiology (1)
- COVID 19 (1)
- CPE (1)
- Caco‐2 cells (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell culture (1)
- Cell-to-Cell Spread (1)
- ChAdOx1-S (1)
- Congenital CMVinfection (1)
- Corona virus (1)
- Covid-19 (1)
- Cytomegalovirus (CMV) (1)
- Darunavir (1)
- Detection workflow (1)
- Donor screening (1)
- E protein structure (1)
- EGFR pathway (1)
- ELISA (1)
- ER stress (1)
- Endothelial cells (1)
- Epsilon (1)
- FFP3 respirator (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Forensic medicine (1)
- HBV (1)
- HCC recurrence (1)
- HCV (1)
- HEV (1)
- HSCT (1)
- Health care workers (1)
- Hepatitis c (1)
- Heterologous prime-boost (1)
- Human immunodeficiency virus (HIV) (1)
- Hypertension (1)
- IAP (1)
- IFA (1)
- IRF-3 (1)
- IgG (1)
- Immunogenicity (1)
- In vitro (1)
- Inactivation (1)
- Inflammation (1)
- Interferon (1)
- Kappa (1)
- Medical history (1)
- Multivariate analysis (1)
- N501Y (1)
- NF-kB (1)
- NGS (1)
- Omicron variant BA.1 (1)
- Otorhinolaryngological (1)
- PAPR (1)
- POCT (1)
- Pandemic (1)
- Pathology (1)
- Personal protective equipment (1)
- Post mortem examination (1)
- Powered air-purifying respirator (1)
- Protein-translocation (1)
- Proteomics (1)
- Quarantine (1)
- RT-PCR-detection (1)
- Reactogenicity (1)
- SARS CoV 2 (1)
- SARS coronavirus (1)
- SARS-CoV-2 testing (1)
- SARS-CoV-2-specific T cells (1)
- SIRPalpha (1)
- SR-BI (1)
- SVR (1)
- Serology (1)
- Seroprevalence (1)
- Stability (1)
- T cell response (1)
- Travel regulations (1)
- Variant of concern (1)
- VeroE6‐eGFP cells (1)
- Viral hepatitis (1)
- Virological testing (1)
- Virus trapping (1)
- Wastewater-based epidemiology (WBE) (1)
- acute liver failure (1)
- animal experiments (1)
- animal models (1)
- antibody tests (1)
- antiviral (1)
- antiviral agents (1)
- antiviral drugs (1)
- antiviral signaling (1)
- aprotinin (1)
- benfooxythiamine (1)
- booster (1)
- cathepsin L inhibitor (1)
- cell barrier integrity (1)
- cell culture (1)
- cerebrospinal fluid (1)
- chelator (1)
- coagulation (1)
- coagulopathy (1)
- contact lens solution (1)
- delta (1)
- diagnostic test (1)
- direct-acting antivirals (1)
- drug discovery (1)
- drug repurposing (1)
- drug screening (1)
- elderly (1)
- famotidine (1)
- flavivirus entry factor (1)
- gargle lavage (1)
- genetic diversity (1)
- global diversity (1)
- hemodialysis (1)
- hepatitis B surface antigen (1)
- hepatitis C virus (1)
- hepatitis D (1)
- hepatitis E (1)
- high throughput (1)
- histamine (1)
- host immune response (1)
- human monoclonal antibody (1)
- human-liver chimeric mouse model (1)
- immunity (1)
- immunosenescence (1)
- immunosuppression (1)
- infection model (1)
- inflammation (1)
- interferon induction (1)
- interferon sensitivity (1)
- intranasal administration (1)
- itraconazole (1)
- live cell imaging (1)
- liver transplantation (1)
- mRNA-1273 (1)
- mRNA1273 (1)
- mesenchymal stromal cells (1)
- mice (1)
- molecular surveillance (1)
- monkeypox (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- multimorbidity (1)
- nasal swab (1)
- natural selection (1)
- neutralization (1)
- neutralizing antibody (1)
- nucleotide analogue (1)
- orthopoxvirus (1)
- oxLDL (1)
- oxythiamine (1)
- pentose phosphate pathway (1)
- phenotypic screening; (1)
- poxvirus (1)
- prevention (1)
- qRT-PCR detection (1)
- re-emerging virus (1)
- reactivation (1)
- self-collected samples (1)
- semen (1)
- seroconversion (1)
- serology (1)
- severe acute respiratory syndrome coronavirus (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- spike mutation (1)
- spike protein (1)
- stem cells (1)
- surrogate ELISA (1)
- tear (1)
- test protocol (1)
- thrombosis (1)
- toll-like receptor (1)
- topical administration (1)
- transduction (1)
- transferrin (1)
- transmission and vector control (1)
- vaccine, (1)
- variant of concern (1)
- variants of concern (1)
- virus (1)
- wastewater-based epidemiology (WBE) (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
Background & Aims: Hepatitis C virus (HCV) cell entry is mediated by several cell surface receptors, including scavenger receptor class B type I (SR-BI). Oxidized low density lipoprotein (oxLDL) inhibits the interaction between HCV and SR-BI in a noncompetitive manner. We tested whether serum oxLDL levels correlate with sustained virologic response (SVR) rates after interferon-based treatment of chronic hepatitis C.
Methods: Baseline oxLDL was determined in 379 participants with chronic HCV genotype 1 infection from the INDIV-2 study using a commercial enzyme-linked immunosorbent assay. The mechanistic in vitro studies used full-length and subgenomic HCV genomes replicating in hepatoma cells.
Results: In the multivariate analysis, oxLDL was found to be an independent predictor of SVR. Oxidized LDL did not correlate with markers of inflammation (alanine transaminase, ferritin), nor was serum oxLDL affected by exogenous interferon administration. Also, oxLDL did not alter the sensitivity of HCV replication to interferon. However, oxLDL was found to be a potent inhibitor of cell-to-cell spread of HCV between adjacent cells in vitro. It could thus reduce the rate at which new cells are infected by HCV through either the cell-free or cell-to-cell route. Finally, serum oxLDL was significantly associated with the estimated infected cell loss rate under treatment.
Conclusions: Oxidized LDL is a novel predictor of SVR after interferon-based therapy and may explain the previously observed association of LDL with SVR. Rather than being a marker of activated antiviral defenses it may improve chances of SVR by limiting spread of infection to naive cells through the cell-to-cell route.
Objective: Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.
Design: We used virological assays to investigate mTOR signalling on the HCV replication cycle. Furthermore, we analysed HCV RNA levels of 42 HCV-positive transplanted patients treated with an mTOR inhibitor as part of their immunosuppressive regimen.
Results: The mTOR inhibitor rapamycin was found to be a potent inhibitor for HCV RNA replication in Huh-7.5 cells as well as primary human hepatocytes. Half-maximal inhibition was observed at 0.01 µg/mL, a concentration that is in the range of serum levels seen in transplant recipients and does not affect cell proliferation. Early replication cycle steps such as cell entry and RNA translation were not affected. Knockdown of raptor, an essential component of mTORC1, but not rictor, an essential component of mTORC2, inhibited viral RNA replication. In addition, overexpression of raptor led to higher viral RNA replication, demonstrating that mTORC1, but not mTORC2, is required for HCV RNA replication. In 42 HCV-infected liver-transplanted or kidney-transplanted patients who were switched to an mTOR inhibitor, we could verify that mTOR inhibition decreased HCV RNA levels in vivo.
Conclusions: Our data identify mTORC1 as a novel HCV replication factor. These findings suggest an underlying mechanism for the observed benefits of mTOR inhibition in HCV-positive OLT recipients and potentiate further investigation of mTOR-containing regimens in HCV-positive recipients of solid organ transplants.
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Results: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM). Conclusions: Overall, the data do not support the use of DRV for the treatment of COVID-19.
The novel coronavirus SARS-CoV-2 is the causative agent of the acute respiratory disease COVID-19, which has become a global concern due to its rapid spread. Meanwhile, increased demand for testing has led to a shortage of reagents and supplies and compromised the performance of diagnostic laboratories in many countries. Both the World Health Organization (WHO) and the Center for Disease Control and Prevention (CDC) recommend multi-step RT-PCR assays using multiple primer and probe pairs, which might complicate the interpretation of the test results, especially for borderline cases. In this study, we describe an alternative RT-PCR approach for the detection of SARS-CoV-2 RNA that can be used for the probe-based detection of clinical isolates in diagnostics as well as in research labs using a low-cost SYBR green method. For the evaluation, we used samples from patients with confirmed SARS-CoV-2 infections and performed RT-PCR assays along with successive dilutions of RNA standards to determine the limit of detection. We identified an M-gene binding primer and probe pair highly suitable for the quantitative detection of SARS-CoV-2 RNA for diagnostic and research purposes.
Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
(2021)
The novel coronavirus SARS-CoV-2 is the causative agent of the acute respiratory disease COVID-19, which has become a global concern due to its rapid spread. Laboratory work with SARS-CoV-2 in a laboratory setting was rated to biosafety level 3 (BSL-3) biocontainment level. However, certain research applications in particular in molecular biology require incomplete denaturation of the proteins, which might cause safety issues handling contaminated samples. In this study, we evaluated lysis buffers that are commonly used in molecular biological laboratories for their ability to inactivate SARS-CoV-2. In addition, viral stability in cell culture media at 4 °C and on display glass and plastic surfaces used in laboratory environment was analyzed. Furthermore, we evaluated chemical and non-chemical inactivation methods including heat inactivation, UV-C light, addition of ethanol, acetone-methanol, and PFA, which might be used as a subsequent inactivation step in the case of insufficient inactivation. We infected susceptible Caco-2 and Vero cells with pre-treated SARS-CoV-2 and determined the tissue culture infection dose 50 (TCID50) using crystal violet staining and microscopy. In addition, lysates of infected cells and virus containing supernatant were subjected to RT-qPCR analysis. We have found that guanidine thiocyanate and most of the tested detergent containing lysis buffers were effective in inactivation of SARS-CoV-2, however, the M-PER lysis buffer containing a proprietary detergent failed to inactivate the virus. In conclusion, careful evaluation of the used inactivation methods is required especially for non-denaturing buffers. Additional inactivation steps might be necessary before removal of lysed viral samples from BSL-3.
Although vaccination campaigns are currently being rolled out to prevent coronavirus disease (COVID-19), antivirals will remain an important adjunct to vaccination. Antivirals against coronaviruses do not exist, hence global drug repurposing efforts have been carried out to identify agents that may provide clinical benefit to patients with COVID-19. Itraconazole, an antifungal agent, has been reported to have activity against animal coronaviruses. Using cell-based phenotypic assays, the in vitro antiviral activity of itraconazole and 17-OH itraconazole was assessed against clinical isolates from a German and Belgian patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Itraconazole demonstrated antiviral activity in human Caco-2 cells (EC50 = 2.3 µM; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay). Similarly, its primary metabolite, 17-OH itraconazole, showed inhibition of SARS-CoV-2 activity (EC50 = 3.6 µM). Remdesivir inhibited viral replication with an EC50 = 0.4 µM. Itraconazole and 17-OH itraconazole resulted in a viral yield reduction in vitro of approximately 2-log10 and approximately 1-log10, as measured in both Caco-2 cells and VeroE6-eGFP cells, respectively. The viral yield reduction brought about by remdesivir or GS-441524 (parent nucleoside of the antiviral prodrug remdesivir; positive control) was more pronounced, with an approximately 3-log10 drop and >4-log10 drop in Caco-2 cells and VeroE6-eGFP cells, respectively. Itraconazole and 17-OH itraconazole exert in vitro low micromolar activity against SARS-CoV-2. Despite the in vitro antiviral activity, itraconazole did not result in a beneficial effect in hospitalized COVID-19 patients in a clinical study (EudraCT Number: 2020-001243-15).
Due to globally rising numbers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, resources for real-time reverse-transcription polymerase chain reaction (rRT-PCR)-based testing have been exhausted. In order to meet the demands of testing and reduce transmission, SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag-RDTs) are being considered. These tests are fast, inexpensive, and simple to use, but whether they detect potentially infectious cases has not been well studied. We evaluated three lateral flow assays (RIDA®QUICK SARS-CoV-2 Antigen (R-Biopharm), SARS-CoV-2 Rapid Antigen Test (Roche)), and NADAL® COVID-19 Ag Test (Nal von Minden GmbH, Regensburg, Germany) and one microfluidic immunofluorescence assay (SARS-CoV-2 Ag Test (LumiraDx GmbH, Cologne, Germany)) using 100 clinical samples. Diagnostic rRT-PCR and cell culture testing as a marker for infectivity were performed in parallel. The overall Ag-RDT sensitivity for rRT-PCR-positive samples ranged from 24.3% to 50%. However, for samples with a viral load of more than 6 log10 RNA copies/mL (22/100), typically seen in infectious individuals, Ag-RDT positivity was between 81.8% and 100%. Only 51.6% (33/64) of the rRT-PCR-positive samples were infectious in cell culture. In contrast, three Ag-RDTs demonstrated a more significant correlation with cell culture infectivity (61.8–82.4%). Our findings suggest that large-scale SARS-CoV-2 Ag-RDT-based testing can be considered for detecting potentially infective individuals and reducing the virus spread.
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serological assays are urgently needed for rapid diagnosis, contact tracing, and for epidemiological studies. So far, there is limited data on how commercially available tests perform with real patient samples, and if positive tested samples show neutralizing abilities. Focusing on IgG antibodies, we demonstrate the performance of two enzyme‐linked immunosorbent assay (ELISA) assays (Euroimmun SARS‐CoV‐2 IgG and Vircell COVID‐19 ELISA IgG) in comparison to one lateral flow assay (FaStep COVID‐19 IgG/IgM Rapid Test Device) and two in‐house developed assays (immunofluorescence assay [IFA] and plaque reduction neutralization test [PRNT]). We tested follow up serum/plasma samples of individuals polymerase chain reaction‐diagnosed with COVID‐19. Most of the SARS‐CoV‐2 samples were from individuals with moderate to the severe clinical course, who required an in‐patient hospital stay. For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5‐9) and from 93.8% to 100% for the later period (days 10‐18).
Direct acting antivirals (DAAs) revolutionized the therapy of chronic hepatitis C infection. However, unexpected high recurrence rates of hepatocellular carcinoma (HCC) after DAA treatment became an issue in patients with advanced cirrhosis and fibrosis. In this study, we aimed to investigate an impact of DAA treatment on the molecular changes related to HCC development and progression in hepatoma cell lines and primary human hepatocytes. We found that treatment with sofosbuvir (SOF), a backbone of DAA therapy, caused an increase in EGFR expression and phosphorylation. As a result, enhanced translocation of EGFR into the nucleus and transactivation of factors associated with cell cycle progression, B-MYB and Cyclin D1, was detected. Serine/threonine kinase profiling identified additional pathways, especially the MAPK pathway, also activated during SOF treatment. Importantly, the blocking of EGFR kinase activity by erlotinib during SOF treatment prevented all downstream events. Altogether, our findings suggest that SOF may have an impact on pathological processes in the liver via the induction of EGFR signaling. Notably, zidovudine, another nucleoside analogue, exerted a similar cell phenotype, suggesting that the observed effects may be induced by additional members of this drug class.
This case series assessed a commercial airline flight from Tel Aviv, Israel, to Frankfurt, Germany, that occurred on March 9th, 2020. Among 102 passengers on a Boeing 737-900 aircraft were 24 members of a tourist group. Starting 7 days earlier, the group had contact with a hotel manager who later received a diagnosis of coronavirus disease 2019 (COVID-19). No member of the group had received a diagnosis of COVID-19 before the flight, and no measures to prevent transmission (eg, wearing of masks) had been applied. The flight duration was 4 hours 40 minutes.